Healthcare / BiotechnologyNasdaqCM
$2.07
+0.09 (+4.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-14.5M · quality 30.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-287.9%
↓Gross Margin
20.0%
↓Debt/Equity
2.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-57.9%
FCF CAGR
—
FCF margin
-24693.2%
FCF / Net income
1.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $54232.0 · net income $-8.0M · FCF $-13.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $54232.00 | $54232.00 | $2.6M | $2.8M | $6.7M | — | $4.1M |
| Net Income | $-8.0M | $-8.0M | $-30.0M | $-25.0M | $-14.9M | $-12.9M | $-5.8M |
| EBITDA | $-5.7M | $-5.7M | $-27.7M | $-23.6M | $-14.1M | $-12.8M | $-5.3M |
| EPS | -10.63 | -10.63 | -30.80 | -28.00 | -16.80 | -27.60 | — |
| Gross Margin | 20.0% | 20.0% | 37.4% | 19.7% | 38.5% | — | — |
| Operating Margin | -20757.6% | -20757.6% | -1076.4% | -905.0% | -224.3% | — | -142.1% |
| Net Margin | -14677.1% | -14677.1% | -1169.7% | -879.5% | -221.7% | — | -141.5% |
| Balance Sheet | |||||||
| Debt/Equity | 2.46 | 2.46 | -2.02 | 0.47 | 0.17 | 0.00 | — |
| Current Ratio | 0.09 | 0.09 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-13.4M | $-13.4M | $-14.5M | $-28.7M | $-20.7M | $-11.0M | $-10.6M |
| Returns | |||||||
| ROE | -287.9% | -287.9% | 443.5% | -185.7% | -39.8% | -25.1% | 34.7% |
| Valuation | |||||||
| P/B | 1.57 | 1.57 | — | 3.20 | 1.99 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -97.9% | -97.9% | -9.7% | -57.7% | — | — | — |
| EPS Growth | 65.5% | 65.5% | -10.0% | -66.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-73.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-30.80 → -10.63
Residual
-73.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.